Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3".

Blood cancer journal 2022 Apr 07

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3".

Related Questions

Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?

Is there any data on combining the two?